Drugs / ALKS 5461
last change Nov 2017 re-read 2 minutes ago

ALKS 5461

Developed for
major depressive disorder
Investigated by
Alkermes, Inc.

Trials 13 · a red edge is where a trial was stopped

PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 17 trials
Phase 1 NCT02545439 Jul → Oct 2015 Alkermes, Inc. Completed No outcome recorded
Phase 1 NCT02508506 Jul → Dec 2015 impaired renal function disease Alkermes, Inc. Completed No outcome recorded
Phase 1 NCT02521857 Jul → Sep 2015 Alkermes, Inc. Completed No outcome recorded
Phase 1 NCT02479308 Jun → Oct 2015 Alkermes, Inc. Completed No outcome recorded
Phase 1 NCT02452801 May → Dec 2015 Alkermes, Inc. Completed No outcome recorded
Phase 1 NCT02272764 Oct → Nov 2014 Alkermes, Inc. Completed No outcome recorded
Phase 1 NCT02068105 Jan → Mar 2014 Alkermes, Inc. Completed No outcome recorded
Phase 1/21 trial
Phase 1/2 NCT01381107 May → Jul 2011 major depressive disorder Alkermes, Inc. Completed No outcome recorded
Phase 35 trials
Phase 3 NCT02218008 Jul 2014 → Sep 2016 major depressive disorder Alkermes, Inc. Completed No outcome recorded
Phase 3 NCT02158533 May 2014 → Dec 2015 major depressive disorder Alkermes, Inc. Completed No outcome recorded
Phase 3 NCT02141399 May 2014 → Nov 2017 major depressive disorder Alkermes, Inc. Completed No outcome recorded
Phase 3 NCT02158546 May 2014 → Dec 2015 major depressive disorder Alkermes, Inc. Completed No outcome recorded
Phase 3 NCT02085135 Feb → Sep 2014 major depressive disorder Alkermes, Inc. Completed No outcome recorded

Evidence & citations 2 cited values

Every value below carries the sentence it was read from. 13 sources stand behind the page.

FieldValueCited text
Known as ALKS 5461 ClinicalTrials.gov intervention name — accepted as the source's own label NCT02218008
12

NCT02479308

NCT02272764

NCT02545439

NCT02521857

NCT02141399

NCT02068105

NCT01381107

NCT02508506

NCT02158533

NCT02452801

NCT02158546

NCT02085135

Route Other “Sublingual administration once daily for 7 consecutive days.” NCT01381107